Apimeds Pharmaceuticals US (APUS) Share-based Compensation (2023 - 2025)

Apimeds Pharmaceuticals US (APUS) has reported Share-based Compensation for 3 consecutive years, with $1.8 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Share-based Compensation rose 746.76% year-over-year to $1.8 million; the trailing twelve-month figure through Sep 2025 stood at $709871.0 (changed N/A YoY), and the FY2025 full-year result was $2.0 million, up 856.6% from the prior year.
• Share-based Compensation improved to $1.8 million in Q4 2025 per APUS's latest filing, from $709871.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $1.8 million in Q4 2025 and bottomed at $213692.0 in Q4 2023.
• Historically, Share-based Compensation has averaged $929342.8 across 3 years, with a median of $709871.0 in 2025.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation changed 0.0% in 2024, then surged 746.76% in 2025.
• Over 3 years, Share-based Compensation stood at $213692.0 in 2023, then changed by 0.0% to $213692.0 in 2024, then soared by 746.76% to $1.8 million in 2025.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.8 million, $709871.0, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.